These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 8480792)
1. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines. Heller WM Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792 [No Abstract] [Full Text] [Related]
2. Bioequivalence/bioavailability retention samples. Ransom C Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218 [No Abstract] [Full Text] [Related]
4. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
5. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related]
6. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Hendeles L; Hochhaus G; Kazerounian S Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793 [No Abstract] [Full Text] [Related]
7. Generic drug company ordered to upgrade. Lewis C FDA Consum; 1999; 33(4):37. PubMed ID: 10443182 [No Abstract] [Full Text] [Related]
9. NerveCenter: FDA requirements for generic drug applications. Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779 [No Abstract] [Full Text] [Related]
10. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
15. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs. Kefalas CH; Ciociola AA Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264 [No Abstract] [Full Text] [Related]
16. SuperGenerics: a better alternative for biogenerics. Charles SA Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591 [No Abstract] [Full Text] [Related]
17. Making medicines safe. Videau JY Bull World Health Organ; 2001; 79(2):87. PubMed ID: 11242826 [No Abstract] [Full Text] [Related]
19. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
20. Trying times for generic medicines in the USA. Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840 [No Abstract] [Full Text] [Related] [Next] [New Search]